• General
  • Industry
  • Government & Politics
  • Other Language
  • Press Release
  • Home
  • Submit News
  • Contact Us
  • About Us
Pakistan Newswire
Menu
  • General
  • Industry
  • Government & Politics
  • Other Language
  • Press Release
 › Medical/Health Care › Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis

Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis

Web Desk May 31, 2012     No Comment     Medical/Health Care

RESEARCH TRIANGLE PARK, N.C., May 30, 2012 /PRNewswire/ –

Stiefel, a GSK (NYSE:GSK) company, and Welichem Biotech, Inc. (WBI:CN), have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong. WBI-1001 is currently in Phase II clinical development for the treatment of psoriasis and atopic dermatitis. The transaction is subject to approval by Welichem shareholders.

Welichem will receive an initial payment of CAD$35 million and is eligible to receive additional milestone payments upon achievement of certain clinical development milestones and upon commercialization in certain countries following marketing approval from the corresponding regulatory agencies.

Under terms of the agreement, Stiefel has also received a conditional right to acquire further exclusive rights to develop and commercialize WBI-1001 in China, Taiwan, Macao and Hong Kong, collectively. Upon satisfaction of certain conditions, Welichem will receive an additional payment of CAD$15million.

“I’m delighted to build upon Stiefel’s clinical pipeline of novel dermatology assets with the acquisition of WBI-1001,” said Barbara White, Senior Vice President and Head of Research and Development, Stiefel. “We have a strong commitment to patients with skin conditions and are excited to undertake development of this innovative agent.”

About WBI-1001: WBI-1001 is a novel, non-steroidal, topical anti-inflammatory new chemical entity (NCE) that has demonstrated efficacy and safety in Ph1 and Ph2 clinical trials for the treatment of mild to moderate psoriasis[i] and moderate to severe atopic dermatitis[ii] for up to 12 weeks as a single therapy.

About Stiefel, a GSK company
Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel’s dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as a world leader in the skin health industry. To learn more about Stiefel, visit www.stiefel.com.

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Stiefel, a GSK company, cautions investors that any forward-looking statements or projections made by Stiefel, a GSK company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect Stiefel, a GSK company’s operations are described under ‘Financial review & risk section” in GSK’s Annual Report 2011 included as exhibit 15.2 to GSK’s Annual Report on Form 20-F for 2011.

References:
[i] British Journal of Dermatology; 166(4):853-60
[ii] Journal of the European Academy of Dermatology and Venereology,Early View, Article first published online: 12 NOV 2011

Medical/Health Care
Stiefel

 Previous Post

PPI Original Text (PPI-OT) – Pakistan Navy’s Annual Safety Review 2011 Held

― May 30, 2012

Next Post 

A New Facility for the 10-Year Anniversary of GenScript

― May 31, 2012

Related Articles

Asim ― June 7, 2020 | No Comment

Covid-19: 8,049 SOP violations reported across Pakistan: NCOC

A total of 8,049 violations of SOPs have been reported to NCOC from across the country during last 24 hours.

Asim ― June 3, 2020 | No Comment

Ulema appeal for prevention against COVID-19

Asim ― May 31, 2020 | No Comment

Wearing Face masks has been made mandatory in all public places in Islamabad

Asim ― May 31, 2020 | No Comment

CM Punjab stresses to change life style for prevention of coronavirus

Asim ― May 30, 2020 | No Comment

PDMA provides safety equipment to 49 KP hospitals

Asim ― May 30, 2020 | No Comment

PR announces to operate 40 trains till complete control on coronavirus pandemic

Web Desk ― April 17, 2018 | Comment Closed

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

Web Desk ― March 1, 2018 | Comment Closed

گڈسینڈ کا وٹامن کے2 نیو یارک کے ٹائمز اسکوائر اور پیرس ففٹین ڈسٹرکٹ پہنچ گیا، چینی فہم کی مضبوطی دنیا بھر میں لے جاتا ہوا

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search

Monthly Archives

Follow Us

Pages

  • Home
  • Submit News
  • Contact Us
  • About Us

Advertisement

Calendar

January 2021
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Dec    


The strategy of the team behind “Pakistan news Wire.Net” is clear and it is to publish only authentic news as that is what the true journalism demands from any media outlet, and the “Pakistan News Wire. Net”, discourages the practice of opting for illegal approaches in order to get the ratings by any means. The more media outlets opt [...]

Archives

Search

Categories

  • General
  • Industry
  • Government & Politics
  • Other Language
  • Press Release
Copyright © 2020 - Pakistan News Wire. All Rights Reserved.